Evidence map›Paper›PMID 41759736›Full record

ArticleThe Journal of biological chemistry2026

Mutations outside the MR1 antigen binding groove differentially inhibit presentation of exogenous antigens.

Corinna A Kulicke, Chance Lemon, Jason R Krawic, Luisa Maria Nieto Ramirez, Se-Jin Kim, Gitanjali Narayanan, Fikadu G Tafesse, William H Hildebrand, Karen M Dobos, David M Lewinsohn

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Corinna A KulickeDivision of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA. Electronic address: kulicke@ohsu.edu.
Chance LemonDivision of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Jason R KrawicDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Luisa Maria Nieto RamirezDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Se-Jin KimDivision of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA; Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA.
Gitanjali NarayananDepartment of Medicine, Johns Hopkins Hospital, Baltimore, Maryland, USA.
Fikadu G TafesseDepartment of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA; Department of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, Oregon, USA.
William H HildebrandDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Karen M DobosDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
David M LewinsohnDivision of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA; VA Portland Health Care System, Portland, Oregon, USA. Electronic address: lewinsod@ohsu.edu.

Funding

Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
Research Resources and Workforce Development for the Rocky Mountain Regional Biocontainment Laboratory at Colorado State UniversityUC7AI180308 · NIAID · COLORADO STATE UNIVERSITY · PI Karen Marie Dobos · 2023 to 2026
$13.5M
T cell recognition of the MR1 presented microbial metabolomeR01AI147954 · NIAID · UNIVERSITY OF CHICAGO · PI ADAMS, ERIN JUNE, HILDEBRAND, WILLIAM · 2019 to 2023
$7.3M
Regional Biocontainment Laboratory (RBL) Upgrade for Colorado State University (CSU)G20AI167348 · NIAID · COLORADO STATE UNIVERSITY · PI DOBOS, KAREN MARIE · 2021 to 2022
$6.5M
Multidisciplinary Research Training in Pulmonary MedicineT32HL083808 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI LEWINSOHN, DAVID M., SLATORE, CHRISTOPHER G. · 2008 to 2025
$5.3M
Lung Resident, MR1-Restricted T Cells: Association with Differential Outcomes Following Exposure to M. TuberculosisR01AI134790 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI LEWINSOHN, DAVID M., WALZL, GERHARD · 2018 to 2022
$3.3M
Determining the role of sphingolipids in Mycobacterium tuberculosis infectionR01AI141549 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI TAFESSE, FIKADU G. · 2020 to 2025
$2.4M
High Performance Computing and Machine Learning Infrastructure for Oregon Life SciencesS10OD034224 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLROTT, KYLE · 2023 to 2023
$2.0M
BLRD VA I01 BX000533NCATS NIH HHS UL1 TR002369NHLBI NIH HHS T32 HL083808NIAID NIH HHS G20 AI167348NIAID NIH HHS R01 AI134790NIAID NIH HHS R01 AI141549NIAID NIH HHS R01 AI147954NIAID NIH HHS UC7 AI180308NIH HHS S10 OD034224
6 · The paper itself

Abstract

The antigen presenting molecule major histocompatibility complex class I-related protein 1 (MR1) binds small molecule metabolites derived from the microbial riboflavin biosynthetic pathway and presents them at the cell surface for surveillance by MR1-restricted mucosal-associated invariant T cells (MAIT cells). MR1 ligands can originate in the extracellular space or in endosomal compartments that contain microbial pathogens. Distinct, complementary antigen processing and presentation pathways enable MR1 to survey diverse intracellular locations and present both exogenous and intracellular antigens. Here, we generated a panel of BEAS-2B MR1 KO cells reconstituted with MR1 proteins mutated at amino acids 9 to 16. The overexpressed mutated MR1 molecules differentially translocated to the cell surface in response to 6-formylpterin and differed in their ability to present mycobacterial antigens to MAIT cell clones. While they barely presented Mycobacterium smegmatis supernatant and other exogenous MAIT cell antigens, their ability to present antigens derived from mycobacterial infection and a 5-amino-6-D-ribitylaminouracil prodrug that requires endosomal processing remained largely intact. Protein coimmunoprecipitation and mass spectrometry-based proteomic analysis showed that mutated MR1 differentially associated with calnexin and β

Indexed as

Antigen PresentationAntigensHistocompatibility Antigens Class IMinor Histocompatibility AntigensMutationCell LineHumansMucosal-Associated Invariant T CellsAntigensHistocompatibility Antigens Class IMinor Histocompatibility AntigensMR1 protein, humanantigen presentationcellular immune responseMAIT cellsMR1-restricted T cellsmucosal immunologyT-cell

Identifiers

PMID41759736
PMCPMC13022675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.